

11 May 2021

## Results of 2021 Annual Meeting of Stockholders

**Minnesota, United States and Melbourne, Australia – 11 May 2021** – Osprey Medical Inc. (ASX:OSP) (**Osprey or the Company**) held its Annual Meeting of Stockholders today and, in accordance with ASX Listing Rule 3.13.2, is pleased to announce that each of the resolutions put to stockholders as set forth in the Notice of Annual Meeting and Proxy Statement dated 20 April 2021 were passed by way of a poll.

*This release has been authorised for lodgement to ASX by Mike McCormick, CEO of Osprey Medical.*

– ENDS –

### Contact details:

#### Investors relations

Ivan Lee

Vesparum Capital

T: (61) 3 8582 4800

[ospreymed@vesparum.com](mailto:ospreymed@vesparum.com)

#### Company

Brendan Case

Company Secretary

M: (61) 410 442 393

[brendan@casegovernance.com.au](mailto:brendan@casegovernance.com.au)

### About Osprey Medical (ASX: OSP)

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast-Induced Acute Kidney Injury (CI-AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

### Foreign Ownership Restriction

Osprey's CHES Depository Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.



**OSPREY MEDICAL INC.**

**RESULT OF ANNUAL MEETING  
(COMMON STOCK) (ASX REPORT)**

ANNUAL MEETING (COMMON STOCK)

Tuesday, 11 May, 2021

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Poll (Manner in which votes were cast in person or by proxy on a poll (where applicable) on a poll at the meeting)			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	Result
1	RE-ELECTION OF DR CHRIS NAVE AS A CLASS II DIRECTOR	NA	825,557,868 99.93%	0 0.00%	597,521 0.07%	488,496	826,155,389 100.00%	0 0.00%	488,496	Carried
2	APPROVAL OF 10% PLACEMENT FACILITY	NA	867,237,747 99.35%	5,672,002 0.65%	0 0.00%	511,996	867,237,747 99.35%	5,672,002 0.65%	511,996	Carried
3	APPROVAL OF AMENDMENT TO 2016 STOCK INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK RESERVED FOR ISSUANCE THEREUNDER	NA	860,190,348 98.49%	13,181,469 1.51%	0 0.00%	49,928	860,190,348 98.49%	13,181,469 1.51%	49,928	Carried
4A	GRANT OF OPTIONS TO MR JOHN ERB, CHAIRMAN OF THE COMPANY	NA	823,516,446 94.42%	48,673,467 5.58%	0 0.00%	1,231,833	823,516,446 94.42%	48,673,467 5.58%	1,231,833	Carried
4B	GRANT OF OPTIONS TO MRS SANDRA LESENFANTS, A DIRECTOR OF THE COMPANY	NA	823,516,446 94.42%	48,673,467 5.58%	0 0.00%	1,231,833	823,516,446 94.42%	48,673,467 5.58%	1,231,833	Carried
4C	GRANT OF OPTIONS TO MR NEVILLE MITCHELL, A DIRECTOR OF THE COMPANY	NA	823,516,446 94.42%	48,673,467 5.58%	0 0.00%	1,231,833	823,516,446 94.42%	48,673,467 5.58%	1,231,833	Carried
5	GRANT OF OPTIONS TO MR MICHAEL MCCORMICK, PRESIDENT & CEO AND A DIRECTOR OF THE COMPANY	NA	870,636,806 99.78%	1,903,106 0.22%	0 0.00%	881,833	870,636,806 99.78%	1,903,106 0.22%	881,833	Carried

\*\* - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item